BTIG Remains Neutral on Valeant (VRX) Post-Q2; Sees Longer-than-Projected Path to Recovery

Go back to BTIG Remains Neutral on Valeant (VRX) Post-Q2; Sees Longer-than-Projected Path to Recovery

Form 8-K Valeant Pharmaceuticals For: Aug 09

August 9, 2016 6:10 AM EDT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

... More